Sildosin as a Male Contraceptive Non Hormonal

In all, 200 healthy, sexually active, fertile male candidates will be assigned 100 in silodosin group and 100 in placebo group. Males using other contraceptive methods will be excluded. Follow up data of total spermatozoa per ejaculate, semen volume and Post-ejaculation urinalysis after 2, 6 and 12 weeks of the studied groups will be recorded. The various side effects reported in the study groups after 12 weeks from the start of the study will be recorded.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Contraception Use

Age range

20 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

male sexually active

Exclusion criteria

male on oral contraceptives Male with female partner on contraceptives

Treatment and study plan

Oral intake of sildosin

Drug

Oral intake of sildosin in male non hormonal contraception

Oral intake of placebo

Other

Intake of placebo to compare effecacy of other group

Primary outcomes

Pregnancy rate in people treated with sildosin as a male contraceptive

Time frame: 3 months

Pregnancy rate in people treated with sildosin as a male contraceptive treatment

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Official study title

A Prospective Study to Evaluate the Efficacy of Silodosin 8 mg as an on-Demand, Reversible, Nonhormonal Oral Contraceptive for Males:

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Sep 26, 2025
Registry last updated: Sep 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting